HiFiBio, ABL Bio to develop SARS-CoV-2 antibody
September 14, 2020 -- HiFiBio Therapeutics has partnered with South Korea-based ABL Bio to advance HFB30132A, a SARS-CoV-2 neutralizing antibody for the treatment of COVID-19 patients.
Neogene Therapeutics to develop personalized cell therapies
September 14, 2020 -- Neogene Therapeutics is pioneering a new class of fully personalized neoantigen T-cell therapies to treat cancer supported by $110 million in series A financing.
Seattle Genetics, Merck partner on 2 oncology drug programs
September 14, 2020 -- Seattle Genetics and Merck will collaborate to develop and commercialize Seattle Genetics' ladiratuzumab vedotin, an antibody-drug conjugate. Separately, Seattle Genetics has granted Merck an exclusive license to commercialize a small-molecule drug for treatment of HER2-positive cancers.
Gilead Sciences to acquire Immunomedics for $21B
September 14, 2020 -- Gilead Sciences will acquire Immunomedics for $88 per share in cash, a transaction that values Immunomedics at approximately $21 billion. The deal is anticipated to close during the fourth quarter of 2020.
Neurocrine, Voyager tout gene therapy clinical results for Parkinson's disease
September 11, 2020 -- Neurocrine Biosciences and Voyager Therapeutics have released data from a phase Ib open-label, three-year efficacy and safety study of NBIb-1817, an investigational gene therapy to improve motor function in patients with Parkinson's disease.
Harbour BioMed, Hualan Genetic partner on antibody programs
September 11, 2020 -- Harbour BioMed and Hualan Genetic Engineering have entered a strategic partnership agreement to develop three proprietary monoclonal and bispecific antibodies from Harbour's portfolio.
Curi Bio launches ComboMat to aid preclinical drug development
September 10, 2020 -- Curi Bio released its new proprietary ComboMat platform, a human induced pluripotent stem cell cardiomyocyte maturation technology with applications in drug discovery, disease modeling, and safety and efficacy screening.
Integral Molecular adds to its antibody discovery platform
September 10, 2020 -- Integral Molecular has developed humanized chicken antibody technology and incorporated it into its MPS antibody discovery platform for multipass membrane proteins. The tech will allow for the isolation of fully humanized antibodies directly from immunized animals.
Totient advances anti-SARS-CoV-2 antibodies with funding, partnerships
September 10, 2020 -- Ginkgo Bioworks and artificial intelligence drug discovery firm Totient have partnered to identify antibodies effective against the novel coronavirus and develop associated therapeutics.
New AI-based company targets discovery of new protein-based therapeutics
September 10, 2020 -- Flagship Pioneering has launched Generate Biomedicines, a new company that will use its machine learning-powered platform for the rapid discovery of new drugs across a range of modalities, including antibodies, peptides, enzymes, and cytokines, and entirely new protein-based therapeutics.
Conferences
ESMO Virtual Congress 2020
September 14-29
Online
2020 ACCP Annual Meeting
September 20-22
Online
BioProcess International West
September 21-25
Online
BioProcess International
September 21-25
Online
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter